Pendulum Therapeutics, founded in 2013, is at the forefront of harnessing microbiome science for health benefits. The company’s commitment to innovation is evident with 13 patents granted and 42 more pending, spotlighting its robust research and development capabilities.
The flagship product, Pendulum Glucose Control, was introduced in 2020 and has garnered clinical validation for reducing blood sugar spikes and A1C levels, marking a significant milestone in their product portfolio.
Leveraging a multidisciplinary team, Pendulum Therapeutics has attracted substantial financial backing, having secured $111 million from prominent investors like Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, AME Cloud Ventures, and the Mayo Clinic. Their most recent funding was a Series C round on 20 February 2024, led by Alumni Ventures.
Based in San Francisco, Pendulum Therapeutics is a promising player in the Biotechnology and Health Care sectors, committed to advancing health solutions grounded in cutting-edge science.
